A recent observational study published in npj Breast Cancer in March 2026 reveals that tumor biology is the primary driver of early breast cancer recurrence, not race. Data shows that Black patients have more than double the rate of aggressive basal-type tumors compared to White patients (11.0% vs. 4.8%). Since 3-year survival depends on these specific genomic risks rather than ancestry, universal molecular subtyping is a critical clinical tool for closing the mortality gap.

While hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer is common, Black women suffer a 40% higher mortality rate that previous research into socioeconomic status has not fully explained, creating a critical clinical gap. Consequently, Sonya Reid from Vanderbilt University Medical Center led a study using MammaPrint and BluePrint signatures to investigate whether inherent tumor genomic differences are the primary contributors to these racial survival disparities beyond standard immunohistochemistry (IHC) classifications.

Therefore, the observational study propensity-matched 509 Black and 509 White females (total N=1,018) with stage I–III disease from the Black Women with Breast Cancer: Etiology, Survival and Treatment Outcomes (BEST) and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles (FLEX) registries to evaluate 3-year Recurrence-Free Survival (RFS) while excluding those with mixed-race identity, male gender, or missing receptor status. Utilizing analytical methods like Cox proportional hazards models and Kaplan-Meier survival curves, the researchers compared clinical features and genomic risk signatures across these racial cohorts within US-based clinical settings to determine the prognostic value of molecular subtyping. This rigorous approach allowed for a direct comparison of outcomes while controlling for potential confounders such as age and menopausal status to pinpoint the biological drivers of recurrence.

Key Clinical Findings of the Study Include:

  • High-Risk Subtype Distribution: The investigation found that Black participants had a significantly higher prevalence of genomically high-risk 2 tumors at 19.8% compared to only 8.4% in White participants.

  • Subtype-Specific Survival Outcomes: The study demonstrated that the 3-year RFS for Basal-Type tumors was only 83.7% compared to 96.5% for Luminal A-Type tumors, regardless of the patient's race.

  • Increased Early Recurrence Risk: Multivariate analysis in the analysis showed that patients with Basal-Type tumors were over 10 times more likely to experience recurrence within 3 years than those with Luminal A-Type disease.

  • Consistent Prognostic Performance: The research confirmed that MammaPrint and BluePrint assays provided equivalent prognostic accuracy across both racial groups, indicating that genomic biology is the primary driver of early survival.

  • Clinical Feature Disparities: The investigation noted that Black participants were significantly more likely than White participants to present with nodal involvement (29.9% vs 17.5%) and higher-grade tumors (76.5% vs 69.9%).

The results suggest that racial survival disparities are significantly influenced by the higher incidence of genomically high-risk disease among Black females, as evidenced by the finding that genomic classification was independently prognostic of 3-year survival.
Thus, the study concludes clinicians may find it helpful to utilize genomic testing for all patients to identify those with aggressive subtypes like Luminal B and Basal-Type who might require more intensive management.
Although this study was limited by its observational design and the absence of data on treatment adherence or social determinants, future investigation into the underlying mechanisms behind the higher frequency of high-risk disease in Black females could prove valuable.

Reference

Reid, S., Venton, L., Whisenant, J.G. et al. Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer. npj Breast Cancer (2026).

Tags:    
Article Source : npj Breast Cancer

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Aashi verma
Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .